SPRO
Spero Therapeutics Inc
NASDAQ: SPRO · HEALTHCARE · BIOTECHNOLOGY
$1.17
+2.63% today
Updated 2026-10-28
Market cap
$62.31M
P/E ratio
7.64
P/S ratio
1.33x
EPS (TTM)
$0.14
Dividend yield
—
52W range
$1 – $3
Volume
0.6M
Spero Therapeutics Inc (SPRO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.17
12-Month target
$2.91
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.1B | $0.0B | $0.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 7.64x (capped 25x) · Margin: 15.70%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.